AACR 2026: ADC Post-Conference Report
Prepared by the Beacon ADC analyst team, the AACR 2026 ADC Post‑Conference Report supports researchers, strategists, and competitive intelligence teams assessing the ADC landscape following the meeting in San Diego. Beacon analysts reviewed the full AACR 2026 abstract set and identified 373 ADC‑relevant presentations, synthesizing them into a focused, analyst‑reviewed resource designed for post‑conference analysis and strategic decision‑making.
What to Expect?
- ADC conference coverage: A complete analysis of all 373 ADC‑relevant abstracts, removing the need to manually review the full AACR programme.
- Clinical and preclinical insights: Structured summaries of key research, including 119 newly disclosed ADC assets across development stages.
- Emerging targets and modalities: Insight into growing focus areas such as novel targets and next‑generation ADC formats, including bispecific and degrader‑based approaches.
- Post‑AACR strategic context: Clear synthesis to support pipeline benchmarking, target prioritization, and competitive positioning.
You May Also Be Interested In…
Learn More About ADC
- The Most Comprehensive Way to Search the ADC Drug Development Landscape: Unique search ontologies based on ADC drug and trial characteristics
- Market Leading Approach to ADC Preclinical & Clinical Data Curation: Manual curation of key ADC research and development data points by ADC research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search ADC company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
